Organisation paid for research Program year 2025 Source: CMS Open Payments

Clearlyderm Dermatology

Neither a doctor nor a teaching hospital

Research payments

$114,224

159 payments

Through program year 2025, Clearlyderm Dermatology is reported as receiving $114,224 in research payments, across 159 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $40,465 4
2024 Research $11,701 91
2023 Research $53,348 58
2022 Research $8,494 5
2021 Research $216 1

Breakdown

Who paid Research payments · program years 2021–2025
  1. Dermavant Sciences, Inc. $71,649 147 payments
  2. Incyte Corporation $41,294 9 payments
  3. Ucb SA $964 1 payment
  4. Amgen Inc. $216 1 payment
  5. AbbVie, Inc. $101 1 payment
Studies the money was for Research payments · program years 2021–2025
  1. An Open Label, Long-Term Extension Study to Evaluate the Safety and Efficacy of Tapinarof Cream 1% in Subjects With Atopic Dermatitis $41,399 28 payments
  2. A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) $40,465 4 payments
  3. A Phase 3 Efficacy and Safety Study of Tapinarof for the Treatment of Moderate to Severe Atopic Dermatitis in Children With Adults $19,378 33 payments
  4. An Open Label, Long-Term Extension Study to Evaluate the Safety and Efficacy of Tapinarof Cream 1% in Subjects With Atopic Dermatitis $10,872 86 payments
  5. Multicenter, Randomized, Parallel Group, Double Blind, Placebo-Controlled (12 17 Years) Including A Single Open Label Arm (6 11 Years) Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol (CZP) in Pediatric Study Participants With Moderate to Severe Chronic Plaque Psoriasis (Pso) $964 1 payment
  6. A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) $829 5 payments
  7. Interchangeability Study - ABP 654 $216 1 payment
  8. A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Level Up) $101 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record